Figure 3From: Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancerThe median survival time (MST), the 1- and 2-year survival rates were 13 months, 50.8% and 37.9% for CRT group and 10 months, 40.4% and 16.50% for RT group (χ2 = 1.811, p = 0.178), respectively.Back to article page